Eindhoven, The Netherlands, 16 May 2022 – STENTiT is pleased to announce that it will be presenting at the EuroPCR in Paris, the World-Leading Course in interventional cardiovascular medicine. On Friday 20 May, STENTiT will show for the first time its latest pre-clinical data in the session “Innovative approaches to complex peripheral interventions”, scheduled from 08:30 –[…]

Eindhoven, The Netherlands, 25 April 2022 – STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8 million seed investment round. The funding facilitates further pre-clinical development and batch production of a regenerative stent for peripheral indications. The investment was made by the Dutch investors NextGen[…]

MedTech Strategist has published an in-depth interview with STENTiT’s CEO Bart Sanders in their latest issue as Start-Up to Watch. Together with Senior Writer/Market Analyst Mary Stuart they focus on the unique potential of STENTiT’s endovascular regenerative technology, while discussing the recent developments in the field as well as lessons learned from the past. About[…]

STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for treatment of cardiovascular diseases, today announced the appointment of its Medical Advisory Board, chaired by Prof. Patrick Serruys and complemented by Prof. Marc van Sambeek and Prof. Yoshinobu Onuma. Bart Sanders, CEO of STENTiT, said: “We are excited to receive the support of[…]

STENTiT, a medical device company bringing a novel class of regenerative stents for sustained endovascular repair, has appointed Dr. Golo von Basum (picture) as its Chief Operating Officer (COO). He will be responsible for the strategic implementation to scale and standardize the product development and company operations. Golo brings more than 16 years of experience in[…]

STENTiT will present at this year’s MedTech Strategist Innovation Summit Dublin to key investors, highlighting how we address the unmet need of sustained vascular repair, with a unique concept of regenerative stents. MedTech Strategist is helping to manage the multitudes of decisions, challenges and opportunities facing the global MedTech industry. In its 8th-year, Innovation Summit[…]

IME Medical Electrospinning, a global leader in electrospun medical devices, today announced that it has entered into a collaboration with Dutch medical device company STENTiT, to join forces in the further development and production of regenerative endovascular support grafts. These resorbable fibrous implants hold the promise to rebuild a new blood vessel inside the existing[…]

Biodegradable implants with stenting capacity, now may regenerate vascular tissue within arteries, as shown in a proof-of-concept study conducted by STENTiT and the Eindhoven University of Technology. These implants hold the potential to restore affected arteries in a minimally invasive way, by exploiting the natural healing response of the body. The results are now published in[…]

On Monday October 21, the Major of Eindhoven and Chairman of the Brainport Foundation, John Jorritsma, received a group of 10 Ambassadors and Trade and Innovation Representatives from foreign embassies in The Netherlands for a Dutch Design Week Economics Relations Event. The aim of this gathering was to organize meetings and interactions with local entrepreneurs[…]

In the highly competitive call of the Horizon 2020 SME instrument, STENTiT was awarded the European Commission’s Seal of Excellence. A recognised high-quality label for business development proposals, evaluated by an international pannel of independent experts on: 1) impact, 2) excellence, and 3) quality and efficiency of implementation. The European recognition to recommend STENTiT for[…]

On Thursday September 27th, STENTiT will participate as one of the finalists in the Shark Tank Competition during the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. TCT is the annual scientific symposium organized by the Cardiovascular Research Foundation (CRF) and the world’s premier educational meeting specializing in interventional cardiovascular medicine. Now in its 31st[…]

During the Global Entrepreneurship Summit (GES), STENTiT proudly participated in the Global Innovation through Science & Technology (GIST) Catalyst pitch competition, organised in collaboration with the Dutch Academic Start-Up Competition. The GIST Catalyst competition began with over 4,000 applications from all over the world, which narrowed down to a list of top 30 companies giving[…]

On Tuesday June 4th, STENTiT will be presenting during the Global Entrepreneurship Summit (GES) 2019 at the World Forum in The Hague. The presentation is part of the GIST Catalyst & Academic Olympics Pitch session held at 15:00 in the Europe room. The program provides Science & Technology entrepreneurs throughout the world with the opportunity[…]

Stentit is one of the ten winners of the Academic Startup Competition. This was announced by a professional jury in Amsterdam in the presence of State Secretary for Economic Affairs and Climate, Mona Keijzer. As a result of the selection, Stentit will be able to pitch at the Global Entrepreneurship Summit (GES) and will be[…]

STENTiT has been nominated for the Academic Startup Competition 2019. Together with 26 other nominees, STENTiT is fighting for a place in the top ten of the most pioneering innovations of science in the Netherlands. The Academic Startup Competition is an initiative of VSNU, the Dutch Academy of Technology and Innovation (AcTI) and StartupDelta. The[…]

STENTiT’s promising first in-vivo data will be presented at the premier international meeting for innovation in cardiovascular systems, ICI 2018 event in Tel Aviv, Israël. Dr. Yoshinobu Onuma MD PhD, from the Erasmus Medical Center of Rotterdam, will present STENTiT’s scientific evidence and clinical applications of the regenerative stent technology in the session; “Stents –[…]

This year at CES Unveiled Amsterdam, Special Envoy StartupDelta Constantijn van Oranje announced the 10 Dutch Breakthrough Technologies of 2018. Among the impressive list, STENTiT was proudly highlighted in the field of Regenerative Medicine. The list has been compiled in consultation with leading academics, investors and industry experts to showcase the next big dutch breakthrough[…]

The health division from the European Institute of Innovation and Technology (EIT Health), provides financial support to STENTiT from the Headstart Funding Programme. The money is granted to support further product development and market validation of the regenerative stent. EIT Health provides funding for early stage companies and SMEs to develop new products and services.[…]